68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment

BJU International

Volumn 117, Issue 5, 2016, Pages 732-739

  Van Leeuwen, Pim J ^a   Stricker, Phillip ^a   Hruby, George ^b,c,d   Kneebone, Andrew ^b,c,d   Ting, Francis ^a   Thompson, Ben ^a   Nguyen, Quoc ^a   Ho, Bao ^e   Emmett, Louise ^e,f  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

68Ga PSMA; biochemical progression; PET CT; prostate cancer; radical prostatectomy; salvage radiation treatment

Indexed keywords

GALLIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG; GALLIUM;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC FOSSA; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT PLANNING; BLOOD; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; RISK FACTOR; SCINTISCANNING; TUMOR RECURRENCE;

AGED; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84959018763     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13397     Document Type: Article

References (24)

1. Cary KC, Punnen S, Odisho AY, et al. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis 2015; 18: 149-54
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65
3. Liauw SL, Pitroda SP, Eggener SE, et al. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2013; 1: 378-84
4. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T,. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol 2010; 22: 46-55
5. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59: 51-60
6. Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008; 88: 10-9
7. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-79
8. King CR,. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012; 1: 104-11
9. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014; 65: 1034-43
10. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 20: 2035-41
11. Choo R, Hruby G, Hong J, et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002; 1: 269-76
12. Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-9
13. Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014; 66: 479-86
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG,. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-40
15. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20
16. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185-90
17. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-72
18. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9
19. Lehman M, Sidhom M, Kneebone AB, et al. FROGG high-risk prostate cancer workshop: patterns of practice and literature review. Part II post-radical prostatectomy. J Med Imaging Radiat Oncol 2014; 58: 392-400
20. Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2015; 24: 513-8
21. Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40: 1629-30
22. Maurer TGJW, Souvatzoglou H, Beer M, et al. PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2015; (abstract e5023)
23. Maurer TGJW, Souvatzoglou H, Beer M, et al. PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. J Clin Oncol 2015; (abstract e16038)
24. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol 2015; 17: 575-84